Health Care

Avantor Inc. (NYSE:AVTR) stock is trading lower on Friday after the company reported worse-than-expected second-quarter 2025 adjusted EPS. The company reported adjusted EPS of 24 cents, marginally below the consensus of 25 cents. AVTR shares are approaching their 52-week low. Track it now here...

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reported upbeat second-quarter earnings and 2025 guidance on Thursday. The company reported a second-quarter 2025 adjusted earnings of 32 cents, down from 56 cents a year ago. Analysts estimated a loss of 79 cents. The company reported quarterly sales of $...

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an operational basis. The company reported adjusted earnings of $2.97, up 12.1% year over year and...

The U.S. Food and Drug Administration approved on Friday, the Novo Nordisk A/S (NYSE:NVO) Alhemo (concizumab-mtci) injection as a once-daily prophylaxis to prevent or reduce the frequency of bleeding episodes in patients 12 years of age and older with hemophilia A or B without inhibitors. In...

Allogene Therapeutics, Inc. (NASDAQ:ALLO) on Friday said it has selected standard fludarabine and cyclophosphamide (FC) as the lymphodepletion regimen to be used in its ALPHA3 study evaluating cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma (LBCL)....

The Trump administration is preparing a pilot program that could allow some Americans on Medicare and Medicaid to access popular and costly weight-loss medications. The plan, still in development, would permit state Medicaid programs and Medicare Part D plans to voluntarily cover GLP-1 drugs such...

Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) are currently up over 20.6% after the company released positive results from its Spectra trial. The Spectra trial evaluates 4D-150 in patients with diabetic macular edema (DME). DME is a serious eye condition that can cause vision loss in people...

On Thursday, the U.S. Food and Drug Administration approved LENZ Therapeutics, Inc.’s (NASDAQ:LENZ) VIZZ (aceclidine ophthalmic solution, previously known as LNZ100) 1.44%, the first and only FDA-approved aceclidine-based eye drop for presbyopia in adults. Presbyopia is an age-related vision...

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% year-over-year, beating the consensus of $8.57. The company reported sales of $3.68 billion, up 4% year over year, beating the consensus of $3....

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss, an improvement from a loss of $3.33 a year ago. The COVID-19 vaccine maker reported quarterly sales of $142 million, beating the consensus of $116.34 million...

In a strong rebuttal to concerns over pharmaceutical innovation, billionaire Mark Cuban, co-founder of Cost Plus Drugs and Shark Tank fame, argued that slashing pharmacy benefit manager (PBM) fees could paradoxically increase research and development (R&D) funding by allowing manufacturers to...

Shares of telehealth company Hims & Hers Health Inc (NYSE:HIMS) are up Thursday afternoon, and at one point, approached a new all-time high. The rally comes amid significant headwinds for major pharmaceutical companies in the lucrative weight-loss drug market. HIMS stock was up most of the day...

The biotechnology sector is witnessing a surge in investor optimism as companies like Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) continue to outperform market expectations. Amid a backdrop of growing demand for innovative treatments, Alnylam’s recent performance highlights the company’s...

Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data on Thursday, revealing inhibition rates of up to 97% in pancreatic cancer cells and almost 90% in colorectal cancer cells. These findings include the company's first evidence of efficacy against the clinically significant KRAS...

On Wednesday, Align Technology Inc. (NASDAQ:ALGN) reported worse-than-expected second-quarter results and issued soft guidance. Second quarter sales increased 3.4% sequentially and were down 1.6% year-over-year to $1.01 billion, versus estimates of $1.06 billion. The dental company reported...